PharmaResearch Co (214450.KQ) Stock Price

PharmaResearch Co Price

KOSDAQ·CLOSED
218,000.00
​
Market closed

Over the last 12 years PharmaResearch Co grew revenue by 32.8% annually, reaching 536.29 B KRW. Earnings per share have grown at 28.2% per year over the last 12 years. For PharmaResearch Co, the net margin of 30.8% is broadly stable versus 30.3% a few years ago. At today's price the dividend yield works out to roughly 1.70%. The payout ratio is around 23% of earnings. The dividend has grown at 33.9% per year over the past 10 years. The consensus 12-month price target for PharmaResearch Co is 612,000.00 KRW, about 180.7% above where the stock trades today. Of 17 analysts, 16 rate the stock a buy — an overall Buy consensus.

PharmaResearch Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaResearch Co business model & stock analysis

PharmaResearch Co Ltd, identified by the ticker symbol 214450.KQ and ISIN KR7214450009, is a South Korean enterprise operating within the health care sector, specifically in the biotechnology industry. Headquartered in Gangneung, located in the Gangwon-Do province, the company has established itself as a specialized player in the field of marine biotechnology. The firm's core operational focus lies in the research and development of refined raw materials designed for cell and tissue regeneration. This scientific foundation supports the company's broader commercial activities, which include the production and sale of regenerated products across multiple sectors. These product categories encompass pharmaceuticals, medical devices, and cosmetics, reflecting a diverse application of its technological capabilities in health and personal care markets. The company initially entered the public markets through an initial public offering on July 24, 2015, marking a significant milestone in its corporate development and providing a platform for potential growth and capital expansion. While the primary market for its products is the domestic South Korean market, the company's strategic positioning within the biotechnology sector highlights its commitment to leveraging marine resources for advanced biological applications. Beyond its core biotechnology and manufacturing operations, PharmaResearch Co Ltd maintains a diversified business portfolio that includes venture investment and real estate leasing activities. These additional ventures contribute to the company's overall financial structure and operational breadth, although the primary emphasis remains on its scientific research and product development in the regeneration field. The company's digital presence is maintained through its official website at http://pharmaresearch.co.kr/, serving as a resource for stakeholders and partners seeking information on its ongoing projects and corporate updates. As a listed entity on the Korean market, PharmaResearch Co Ltd continues to navigate the competitive landscape of the biotechnology industry, relying on its specialized expertise in marine bio technology to drive innovation and deliver value through its regenerated products and related services.

Frequently asked questions about PharmaResearch Co

Analysts currently set an average price target of 630,823.64 KRW for the PharmaResearch Co stock (median: 612,000.00 KRW), implying +189.4 % versus the latest price. The consensus is based on 17 analyst ratings.

18 analysts currently rate the PharmaResearch Co stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect PharmaResearch Co to generate revenue of 692.88 B KRW and earnings per share of 19,465.57 KRW.

Converted at the current exchange rate, the PharmaResearch Co share trades at 144.67 EUR (218,000.00 KRW).

The PharmaResearch Co share (214450.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (214450.KQ).

The expected revenue of PharmaResearch Co is 692.88 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PharmaResearch Co is 202.24 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PharmaResearch Co is currently 11.20. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PharmaResearch Co stock.

The price-to-sales ratio (P/S) of PharmaResearch Co is currently 3.27. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PharmaResearch Co stock.

The Eulerpool Quality Score for PharmaResearch Co is 9/10.

The ISIN of PharmaResearch Co is KR7214450009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of PharmaResearch Co is 214450.KQ. The ticker symbol is used to trade PharmaResearch Co shares on the stock exchange.

Fair ValueTerminal
178,760.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Jul 24, 2015
ISIN
KR7214450009
Cusip
Y6S297101
Market capitalization
2.24 T KRWMega Cap
52-Week Range
PEG
0.98
P/E ratio
P/Ee 2026
11.10
P/Ee 2027
9.14
P/Ee 2028
7.48
P/Ee 2029
—
P/S
P/Se
3.27
EV/EBIT
9.65
P/B Ratio
3.26
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
23.94 %
Dividend
Dividend yield
1.70 %
Est. Dividend Yield
2.04 %
Payout Ratio
23.28 %
Dividend growth Ø5Y
43.88 %
Dividend payments per year
1
Dividend paid since
11 years
Dividend not reduced since
11 years
Dividend increased since
6 years
Dividend withholding tax
22.00 %
Last updated Nov 5, 2026, 9:21 AM

PharmaResearch Co Peer Group

PharmaResearch Co Ticker

KOSDAQ · 214450.KQ

PharmaResearch Co FIGI

214450:KS · BBG009DTHPP1214450:KQ · BBG009DTHPR9